- CSR Summary Not Yet Available
- NCT00454584
- Primary Citation
- Data Specification Not Available
Trial Information
Generic NameUstekinumabProduct NameSTELARA®Therapeutic AreaSkin and Connective Tissue DiseasesEnrollment903% Female32.1%% White90.6%
Product ClassAntipsoriaticsSponsor Protocol NumberC0743T12Data PartnerJohnson & JohnsonCondition StudiedPsoriasisMean/Median Age (Years)45.2
Supporting Documentation
- Collected Datasets Available
- Data Definition Specification Available
- Protocol with Amendments Available
- Statistical Analysis Plan Available
- Clinical Study Report Available
Approved Data Requests Associated with this Trial
- 2024-0808 : Making Effectiveness Research better by meta-analysing Trial and Real World Evidence in Immune-Mediated inflammatory Diseases (MERMAID)
- 2024-0716 : Validation of causal machine learning methods to identify heterogeneous treatment effects
- 2024-0356 : Combining clinical trials with external data: applications in the YODA database
- 2022-4894 : Systemic pharmacological treatments for chronic plaque psoriasis: A Systematic Review and an Individual-Patient Data Network Meta-Analysis of RCTs
- 2019-4067 : Evidence-generation for biologics in pediatric studies
- 2019-3865 : Alternative Data Presentation For Treatment Outcomes in Psoriasis
- 2015-0339 : Impact of the dose of immunomodulators on pharmacokinetics of biologics: Patient level meta-analysis of randomized controlled trials